-
1
-
-
77950258317
-
Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: Pooled analysis of two randomised controlled trials
-
for the CVT group. Abstract/Free Full Text
-
Wacholder S, Chen BE, Wilcox A, Macones G, Gonzalez P, Befano B, et al; for the CVT group. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ 2010;340:c712.[Abstract/Free Full Text]
-
(2010)
BMJ
, vol.340
-
-
Wacholder, S.1
Chen, B.E.2
Wilcox, A.3
Macones, G.4
Gonzalez, P.5
Befano, B.6
-
2
-
-
0008348082
-
-
Revision 5
-
European Medicines Agency. Cervarix European public assessment report. Revision 5. 2009.www.ema.europa.eu/humandocs/Humans/EPAR/cervarix/cervarix.htm.
-
(2009)
Cervarix European Public Assessment Report
-
-
-
3
-
-
84881316130
-
Vaccines, blood and biologics
-
US Food and Drug Administration: vaccines, blood and biologics. Cervarix. www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186957.htm.
-
Cervarix
-
-
-
4
-
-
84881311267
-
Suspected adverse reaction analysis
-
UK Medicines and Healthcare products Regulatory Agency. Suspected adverse reaction analysis.Cervarix human papillomavirus (HPV) vaccine. 2010. www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/ Product-specificinformationandadvice/HumanpapillomavirusHPVvaccine/CON023340.
-
(2010)
Cervarix Human Papillomavirus (HPV) Vaccine
-
-
-
5
-
-
77951705195
-
-
Health Protection Agency. Annual HPV vaccine uptake in England: 2008/09. 2010. www.dh.gov.uk/dr-consum-dh/groups/dh-digitalassets/@dh/@en@ps/documents/ digitalasset/dh-111676.pdf.
-
(2010)
Annual HPV Vaccine Uptake in England: 2008/09
-
-
-
6
-
-
67651049056
-
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women
-
[CrossRef][Web of Science][Medline]
-
Paavonen J, Naud P, Salmeron J, Wheeler C, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-314[CrossRef][Web of Science][Medline]
-
(2009)
Lancet
, vol.374
, pp. 301-314
-
-
Paavonen, J.1
Naud, P.2
Salmeron, J.3
Wheeler, C.4
Chow, S.N.5
Apter, D.6
-
7
-
-
70449717381
-
Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009
-
WHO
-
WHO. Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009. Wkly Epidemiol Rec 2009;32:325-332
-
(2009)
Wkly Epidemiol Rec
, vol.32
, pp. 325-332
-
-
-
8
-
-
73349127849
-
Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine
-
[CrossRef][Web of Science][Medline]
-
Dana A, Buchanan KM, Goss MA, Seminack MM, Shields KE, Korn S, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009;114:1170-1178[CrossRef][Web of Science][Medline]
-
(2009)
Obstet Gynecol
, vol.114
, pp. 1170-1178
-
-
Dana, A.1
Buchanan, K.M.2
Goss, M.A.3
Seminack, M.M.4
Shields, K.E.5
Korn, S.6
-
9
-
-
73349128149
-
Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: A combined analysis of five randomized controlled trials
-
[CrossRef][Web of Science][Medline]
-
Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009;114:1179-1188[CrossRef][Web of Science][Medline]
-
(2009)
Obstet Gynecol
, vol.114
, pp. 1179-1188
-
-
Garland, S.M.1
Ault, K.A.2
Gall, S.A.3
Paavonen, J.4
Sings, H.L.5
Ciprero, K.L.6
-
10
-
-
67651031934
-
Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials
-
[Web of Science][Medline]
-
Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009;5:332-340[Web of Science][Medline]
-
(2009)
Hum Vaccin
, vol.5
, pp. 332-340
-
-
Descamps, D.1
Hardt, K.2
Spiessens, B.3
Izurieta, P.4
Verstraeten, T.5
Breuer, T.6
-
11
-
-
77649271813
-
Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK
-
[CrossRef][Web of Science][Medline]
-
Cuzick J, Castanon A, Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br J Cancer 2010;102:933-939 [CrossRef][Web of Science][Medline]
-
(2010)
Br J Cancer
, vol.102
, pp. 933-939
-
-
Cuzick, J.1
Castanon, A.2
Sasieni, P.3
-
12
-
-
32144454702
-
Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: Systematic review and meta-analysis
-
[CrossRef][Web of Science][Medline]
-
Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367:489-498[CrossRef][Web of Science][Medline]
-
(2006)
Lancet
, vol.367
, pp. 489-498
-
-
Kyrgiou, M.1
Koliopoulos, G.2
Martin-Hirsch, P.3
Arbyn, M.4
Prendiville, W.5
Paraskevaidis, E.6
|